Navigation Links
Theranostics Health Signs Research Collaboration Agreement
Date:5/15/2008

ROCKVILLE, Md., May 15 /PRNewswire/ -- Theranostics Health (THX) today announced that it has entered into a three-year master research collaboration agreement with Duke University. This relationship will provide Duke investigators access to the company's core technologies: Laser Capture Microdissection (LCM) and Reverse Phase Protein Microarray (RPMA). The proprietary combination of these technologies provides a powerful mechanism to accurately and reliably measure the aberrant protein signaling and protein molecular networks used by tumor cells obtained directly from a patient's biopsy. This information can be used to investigate patient-specific treatments and individual treatment regimens, and also, to better understand the mechanisms of tumorigenesis in order to discover and develop new, safer and more effective therapies.

According to Dr. Neil Spector, Director of Duke's Translational Research Oncology Program, "those of us at Duke who are going to participate in this umbrella agreement with Theranostics Health are excited about the insight this collaboration may provide on the use of phosphoproteomics to shed light on the complexities of the signaling networks that regulate tumor cell growth, survival, migration/invasion, and resistance to targeted therapies. We are intrigued by the possibility of applying this information to investigate more effective therapies for our patients."

"The future of cancer treatment is personalized, targeted therapies and patient stratification for clinical trials," says Dr. Emanuel Petricoin, CSO of Theranostics Health. "We believe that this research collaboration with Duke, one of the top institutions in the world, will provide an important next step for our company in both research applications at the bench as well as working together with Duke investigators during phase I, II and III clinical trials."

Dr. Danong Chen, President and CEO of Theranostics Health, is equally optimistic about the master research agreement with Duke. "We are very pleased to begin collaboration with a nationally-recognized center of excellence and believe that Duke shares our vision of shaping a new paradigm in disease management. This relationship demonstrates the value of this technology for impacting healthcare delivery."

About Theranostics Health

Theranostics Health, LLC is a privately-held company founded in 2006 and based in Rockville, MD. Its core technology is the proprietary combination of Laser Capture Microdissection (LCM) and Reverse Phase Protein Microarray (RPMA) both developed by the company's co-founders Drs. Lance Liotta and Emanuel Petricoin III. The technology measures the activity of a large number of biomarkers, enabling pharmaceutical companies to accurately profile their drug candidates to more efficiently develop safer, more effective therapeutics. More importantly, it enables physicians to tailor optimized therapies to their patients based on the biomarker profile of each individual patient, providing safer and more effective therapies. Theranostics Health is currently working with 5 of the top 10 global pharmaceutical companies in their drug R&D efforts. For more information please email info@theranosticshealth.com or visit http://www.theranosticshealth.com.


'/>"/>
SOURCE Theranostics Health, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NIH Grants Exclusive License to Theranostics Health
2. SXC Health Solutions to present at the FBR Capital Markets 12th Annual Spring Investor Conference
3. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction
4. The 2008 AMIA Spring Congress to Showcase Best Practices and Innovations in Biomedical and Health Informatics Research and Education
5. Diagnostic Health Corporation Names Robert E. Gontarek as COO
6. Vancouver Coastal Health Authority Makes Waves With Patient Flow
7. Guardian Survey: Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement
8. Healthy Farms, Healthy Schools Grant Applications Available
9. Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference
10. HealthSTAR Public Relations Hires Hayley Soffer, Executive Vice President
11. IADR and GlaxoSmithKline Consumer Healthcare announce winners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” Pate ... year donated money to the Triumph Over Kid Cancer foundation. Each year, 175,000 children ... those children. James saw firsthand the effect of the critical funding gap for research ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) ... a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background in ... “It is with considerable pleasure to welcome back Dr. Kim to the CDG team” ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from ... in breast surgery. Covering topics from cosmetic breast augmentation to breast ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... From a ... are released almost daily linking gut health to chronic disease, mental health and general ... Year ” as an important resolution to consider. , For one Charlottesville restaurant, good ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced ... to compete in the Boston Marathon on April 17. From first-time participants to ... marathon to join Team V and support the Foundation’s mission to declare victory over ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 The Philadelphia Pediatric Medical ... developing medical devices for children. The Consortium chose ... seed grants of $50,000 each. The devices under ... nerve signals, a hand-operated rapid blood delivery system for emergency ... babies. ...
(Date:1/18/2017)...   Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to restore ... the Company,s operating results for 2016 and an outline ... Company described in its recent 10-K filing with the ... The Company,s contract laboratory completed its evaluation of NovaDerm®, ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: